PNC-27
PNC-27 is a 32-amino-acid synthetic peptide derived from the p53 tumor suppressor protein, developed in preclinical research for its capacity to selectively lyse cancer cells. That research has not translated into human trials — no established clinical dosing protocol exists, and community use is too sparse to describe any modal pattern in what individuals are actually running. Every human application is off-label and compounded, with no clinical safety or efficacy record to anchor it.
Research Evidence
Evidence shape
No registered clinical trials extracted for PNC-27 yet. Off-label / exploratory data exists for 1 additional indication (Preclinical / mechanistic research).
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
Price
price offers can be sorted by column
Dosing & Protocol
How PNC-27 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- not defined in current trials
- Timing
- not defined in current trials
- Route
- subQ | IV
- Cycle
- not defined in current trials
PNC-27 is exclusively in preclinical research, with no active clinical trials listed on clinicaltrials.gov for human indications or dosage protocols.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for PNC-27, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.